Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.

Abstract

While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

• Authors: Janna A Hol, Marry M van den Heuvel-Eibrink, Norbert Graf, Kathy Pritchard-Jones, Jesper Brok, Harm van Tinteren, Lisa Howell, Arnauld Verschuur, Christophe Bergeron, Leo Kager, Serena Catania, Filippo Spreafico, Annelies M C Mavinkurve-Groothuis
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 65 Issue 2 (Feb 2018) ISSN: 1545-5017 [Electronic] United States
• PMID: 29077255 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
• Copyright: © 2017 Wiley Periodicals, Inc.

Chemical References

• Irinotecan
• Camptothecin

Topics

• Adolescent
• Camptothecin (administration & dosage, analogs & derivatives)
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Humans
• Irinotecan
• Kidney Neoplasms (drug therapy)
• Male
• Risk Factors
• Wilms Tumor (drug therapy)